Just see how Benitec IPO and Regenx bio IPO : which Management is better?
Benitec Biopharma (NASDAQ:
BNTC), the only IPO this week, fell 13.5% on its first day trading. The company raised $14 million by offering 1.5 million ADSs at $9.21 on Tuesday, a 23% discount to its last price on the Australian Stock Exchange. Benitec, which is developing a gene therapy platform based on DNA-directed RNA interference, originally filed terms on July 27 for a $65 million offering only to postpone its IPO ten days later. On August 10, the company revised its terms downward to $25 million, followed by another downward revision on August 13 to $15 million. In a week where the Nasdaq Biotechnology Index fell 4.5%, Benitec underperformed, trading 13% below its offer price as of midday Friday.
REGENXBIO Surges on Debut - REGENXBIO (NASDAQ:
RGNX) shares
surged on their debut on Thursday. The company had already increased its IPO price to $22. On Thursday, the stock closed 38.41% higher at $30.45.
